Crossmark

Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)

Crossref DOI link: https://doi.org/10.1038/s41409-022-01830-3

Published Online: 2022-09-22

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gavriilaki, Eleni https://orcid.org/0000-0002-8883-8208
Labopin, Myriam https://orcid.org/0000-0003-4514-4748
Sakellari, Ioanna

Salmenniemi, Urpu

Yakoub-Agha, Ibrahim https://orcid.org/0000-0003-4524-8782
Potter, Victoria

Berceanu, Ana

Rambaldi, Alessandro

Hilgendorf, Inken https://orcid.org/0000-0003-2038-9730
Kröger, Nicolaus https://orcid.org/0000-0001-5103-9966
Mielke, Stephan

Zuckerman, Tsila https://orcid.org/0000-0002-6204-977X
Sanz, Jaime https://orcid.org/0000-0001-6934-4619
Busca, Alessandro https://orcid.org/0000-0001-5361-5613
Ozdogu, Hakan https://orcid.org/0000-0002-8902-1283
Anagnostopoulos, Achilles https://orcid.org/0000-0003-4384-9031
Savani, Bipin https://orcid.org/0000-0002-3304-9965
Giebel, Sebastian https://orcid.org/0000-0002-4827-4401
Bazarbachi, Ali https://orcid.org/0000-0002-7171-4997
Spyridonidis, Alexandros https://orcid.org/0000-0003-3097-2532
Nagler, Arnon https://orcid.org/0000-0002-0763-1265
Mohty, Mohamad https://orcid.org/0000-0002-7264-808X
License Information

Text and Data Mining valid from 2022-09-22

Version of Record valid from 2022-09-22
More Information

Article History

Received: 8 October 2021

Revised: 26 August 2022

Accepted: 8 September 2022

First Online: 22 September 2022

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below